World Sleep Industry ENCYCLOPEDIA

Suanzaoren Extracts

3.1.2

Definition, botanical source, and adjacent products

Suanzaoren extract is a concentrated ingredient made from the dried mature seed of the sour or wild jujube in the family Rhamnaceae, using water, aqueous ethanol, or another defined process. The currently accepted botanical treatment can be written Ziziphus jujuba subsp. spinosa (Bunge) J.Y.Peng, X.Y.Li & L.Li, while materia medica standards commonly retain Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H.F.Chow. Either name needs to be linked to the drug name, seed part, and traceable source; “jujube,” “wild date,” or “zao” alone does not authenticate the ingredient.

This entry is not the sour-jubube fruit pulp, ordinary cultivated jujube fruit, juice, hard stone, mechanically pressed seed oil, whole Ziziphi Spinosae Semen, or a multi-herb proprietary medicine. Raw seed, stir-fried seed, a decoction of crushed material, an alcohol extract, and a saponin- or flavonoid-enriched fraction have different transfer profiles and dose meanings. Results for Suanzaoren decoction, Zao Ren An Shen products, or formulas containing Poria, Schisandra, Salvia miltiorrhiza, gamma-aminobutyric acid, or melatonin cannot automatically be assigned to a single suanzaoren extract.

Processing, extraction, and specification language

Supply documentation should state whether the source is raw or stir-fried, particle size before extraction, solvent, solid-to-liquid conditions, time and temperature, number of extraction cycles, concentration and drying method, actual yield, and carrier. Stir-frying changes relative levels of fatty acids, flavonoids, saponins, and other constituents, so equal weights of raw and processed seed are not necessarily chemically equivalent. Crushing also affects release. Transfer from crude seed to standard decoction, dry extract, and commercial powder therefore needs process-specific verification rather than a generic statement that the material is “traditionally extracted.”

The label should distinguish native extract from a commercial powder containing starch, maltodextrin, or another excipient. It should separately state native extract per serving, crude-drug equivalent, drug-to-extract ratio, and carrier proportion. “10:1” or “equivalent to” a number of grams does not establish exposure to spinosin, jujuboside A, or another constituent unless starting mass, extraction yield, and the denominator after adding carrier are disclosed. Standardizing one marker can improve batch comparability, but the marker value alone does not demonstrate a sleep benefit.

Human sleep evidence and limits on extrapolation

One randomized, double-blind, placebo-controlled crossover feasibility trial was completed by only 12 people with insomnia. It used two grams per day of an encapsulated aqueous-extract granule for four weeks in each treatment period. The Pittsburgh Sleep Quality Index showed a small improvement versus placebo, but period effects were present and most other outcomes were not statistically different. The trial was designed to test feasibility and was too small to establish a stable effect, optimal dose, long-term safety, or performance across populations. Its 5:1 water extract, carrier, and batch do not represent extracts made with other solvents or marker specifications.

A 2023 systematic review included nine randomized trials with 905 participants who had insomnia or sleep disturbance and suggested short-term improvement in patient-reported sleep quality, while noting small samples, variable quality, and mixed long-term findings. The interventions included different single-ingredient products, formulas, and clinical contexts, so a pooled estimate cannot be placed on any arbitrary extract. A 2026 exploratory study completed by 24 participants also lasted four weeks, relied primarily on self-reported scales, and lacked objective sleep-architecture confirmation. These signals justify further research but do not support claims to cure insomnia, increase deep sleep, or replace cognitive behavioral therapy or prescribed care.

Authentication and batch quality

High demand and price create a practical risk of confusion with similar-looking seeds or fruits, including Ziziphus mauritiana seed and Hovenia seed. Intact material can be assessed macroscopically and microscopically; once powdering removes those features, a validated DNA method may be useful at an applicable upstream stage. DNA can be degraded in a highly processed extract, so identity should be locked before extraction and carried forward through supplier records, retained samples, and chemical fingerprints. Color, odor, a regional name, or a photograph cannot authenticate a commercial powder.

An analysis of commercial suanzaoren extracts found large differences in flavonoids, saponins, and fingerprints among suppliers. Representative constituents in some samples were roughly one tenth of those in laboratory water extracts, while another sample lacked detectable jujuboside A and was suspected by the investigators to reflect a different Ziziphus seed or processing route. Procurement should combine spinosin, jujubosides A and B, an appropriate multicomponent fingerprint, and mass balance with solvent, carrier, and yield review. Moisture, microbiological quality, aflatoxins, pesticide residues, heavy metals, residual solvents, and undeclared additions require jurisdiction-appropriate control. One compliant peak cannot exclude dilution, blending, or a mismatched process.

Finished-product selection and outcome review

Product selection should establish the exact species and seed part, raw or stir-fried status, extraction route, native extract per serving, total daily amount, carrier, and every combined ingredient. Tablets, capsules, granules, drinks, and softgels differ in release, sugar, lipid content, swallowing burden, and stability. A certificate of analysis must correspond to the package lot and shelf life. “High spinosin,” “dual saponins,” a protected origin, or third-party testing describes only the stated test scope; none replaces a human study of the finished product.

When use follows professional advice, one to two weeks of baseline records can be collected while bedtime, rise time, light exposure, caffeine, alcohol, and other sleep interventions remain reasonably stable. Track sleep onset, awakenings, total sleep, next-day alertness, work or driving performance, and gastrointestinal effects. Patient-reported scales can show trends, but a consumer wearable’s sleep-stage estimate cannot independently validate efficacy. If improvement is not repeatable and meaningful, or if morning impairment, paradoxical activation, diarrhea, rash, or another adverse effect occurs, stop and review rather than escalating the dose or adding a formula.

Safety, combinations, and referral boundary

Most human studies lasted only weeks. Long-term dose-response, changes after discontinuation, rare adverse effects, and drug interactions remain inadequately characterized for a single standardized extract. The small aqueous-extract trial mainly reported minor events, including softer stools, and another short pilot observed increased bowel-movement frequency. These findings neither establish long-term safety nor prove that a gastrointestinal effect mediates sleep. People with allergy to the seed or excipients, existing diarrhea, or unexplained gastrointestinal symptoms need particular caution.

There are insufficient human interaction data to justify self-combining the extract with alcohol, hypnotics, anxiolytics, antidepressants, antihistamines, or other products that may alter alertness. “Natural” is not evidence of a safe combination. Pregnant or breastfeeding people, children, people with hepatic or renal impairment, those planning a procedure, and anyone who drives or performs safety-critical work should give a clinician or pharmacist the exact product and full ingredient list before deciding. Persistent insomnia, marked daytime sleepiness, loud snoring with witnessed pauses, unusual leg symptoms, major mood deterioration, or thoughts of self-harm requires appropriate assessment; an extract must not delay diagnosis of the cause.

Regulation, supply chain, and industry evaluation

Across jurisdictions, Ziziphi Spinosae Semen may be regulated as crude Chinese materia medica, a processed herbal drug, formula granule, proprietary-medicine ingredient, health food, dietary-supplement ingredient, or another category. Food status, pharmacopoeial inclusion, and traditional use are not interchangeable. Spinosin and jujuboside limits for crude material do not necessarily apply unchanged to a concentrated extract, and registration, listing, a disclaimer, or a laboratory report is not regulatory confirmation that the product treats insomnia. A company must establish ingredient eligibility, manufacturing authorization, labeling, permissible claims, adverse-event reporting, and recall duties for the exact market and product.

Industry evaluation should track planting source and origin, harvest maturity, raw versus stir-fried processing, grinding, identity at intake, extraction yield, carrier changes, multicomponent fingerprint, moisture- and oxygen-barrier packaging, and in-use life. A supplier change requires a new comparability bridge rather than reuse of an old certificate, and studies should disclose lot, process, and delivered dose so that replication addresses the same material. Related entries include whole Ziziphi Spinosae Semen, sour-jujube seed oil, arborvitae seed extract, Poria extract, and multi-ingredient sleep formulas; their evidence, specifications, and risks are not interchangeable and a shared sleep context does not justify stacking them.